Abstract:INTRODUCTION:Vascular cognitive impairment without dementia is very common among the aged and tends to progress to dementia, but there have been no proper large-scale intervention trials dedicated to it. Vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease (hereinafter, subcortical Vascular cognitive impairment without dementia) represents a relatively homogeneous disease process and is a suitable target for therapeutic trials investigating Vascular cognitive impairment without dementia. Preclinical trials showed that dl-3-n-butylphthalide (NBP) is effective for cognitive impairment of vascular origin. METHODS:In this randomized, double-blind, placebo-controlled trial, we enrolled patients aged 50-70 years who had a diagnosis of subcortical Vascular cognitive impairment without dementia at 15 academic medical centers in China. Inclusion criteria included a clinical dementia rating ≥0.5 on at least one domain and global score ≤0.5; a mini-mental state examination score ≥20 (primary school) or ≥24 (junior school or above); and brain magnetic resonance imaging consistent with subcortical ischemic small vessel disease. Patients were randomly assigned to NBP 200 mg three times daily or matched placebo (1:1) for 24 weeks according to a computer-generated randomization protocol. All patients and study personnel were masked to treatment assignment. Primary outcome measures were the changes in Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) and clinician's interview-based impression of change plus caregiver input (CIBIC-plus) after 24 weeks. All patients were monitored for adverse events (AEs). Outcome measures were analyzed for both the intention-to-treat (ITT) population and the per protocol population. RESULTS:This study enrolled 281 patients. NBP showed greater effects than placebo on ADAS-cog (NBP change -2.46 vs. placebo -1.39; P = .03; ITT) and CIBIC-plus (80 [57.1%] vs. 59 [42.1%] patients improved; P = .01; ITT). NBP-related AE were uncommon and primarily consisted of mild gastrointestinal symptoms. DISCUSSION:Over the 6-month treatment period, NBP was effective for improving cognitive and global functioning in patients with subcortical vascular cognitive impairment without dementia and exhibited good safety.

Clinical study on dl-3 n-butylphthalide in improving cerebrovascular reactivity and cognitive function in patients with Binswanger disease

Butylphthalide Improves Cerebrovascular Reactivity in Patients with Severe Intracranial Internal Carotid Artery Stenosis

DL-3-n-butylphthalide improves cerebral hypoperfusion in patients with large cerebral atherosclerotic stenosis: a single-center, randomized, double-blind, placebo-controlled study

The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: A multicentre, randomized, double-blind, placebo-controlled trial

Comparative Study in the Treatment of Acute Ischemic Cerebrovascular Diseases with dl-3-butylphthalide

The Clinical Research of Combination of Butylphthalide and Piracetam in the Treatment of Patients with Vascular Demetia

Effect of dl-3n-butyphthalide on cognitive function and hippocampal nuclear factor-κB expression in vascular dementia rats

Dl-3-n-butylphthalide Regulates Cholinergic Dysfunction in Chronic Cerebral Hypoperfusion Rats

Efficacy and safety of butylphthalide in patients with mild cognitive impairment: a multicentre, randomised, double-blind, placebo-controlled trial (EBMCI study)

dl-3-butylphthalide in the Treatment of Acute Cerebral Infarction

Effects of Dl-3-butylphthalide on Treatment of Acute Ischemic Stroke with Moderate Symptoms: a Multi-Center, Randomized, Double-Blind, Placebo-Control Trial

Effects of Dl-3-butylphthalide Soft Capsules on Treatment of Acute Ischemlc Stroke: Multi-Center, Randomized, Double-Blind, Double-Dummy and Aspirin-Control Study

Effect of 3-n-butylphthalide on brain-derived neurotrophic factor expression in hippocampal CA1 region of vascular dementia rats

Cerebral hemodynamic changes assessment by transcranial doppler ultrasound in patients with acute cerebral infarction before and after treatment with butylphthalide

Effects of Butyphthalide Combined with Idebenone on Inflammatory Cytokines and Vascular Endothelial Functions of Patients with Vascular Dementia

Effectiveness of Butylphthalide on Cerebral Autoregulation in Ischemic Stroke Patients with Large Artery Atherosclerosis (EBCAS Study): A Randomized, Controlled, Multicenter Trial.

Clinical trial of butylphthalide combined with low-dose of rt-PA in treatment of acute cerebral infarction

Dl‐3‐n‐butylphthalide promotes synaptic plasticity by activating the Akt/ERK signaling pathway and reduces the blood–brain barrier leakage by inhibiting the HIF‐1α/MMP signaling pathway in vascular dementia model mice

Effects of 3-n-butylphthalide on memory and Caspase-3 expression in the hippocampal CA1 region of vascular dementia rats

Dl-3-butylphthalide for Acute Ischemic Stroke:A Systematic Review

Effect of Dl-3-butylphthalide on the Expression of Sicam-1 Protein and the Neurological Function Improvement in Patients Subjected to Acute Ischemic Stroke